easYmer HLA-B*15:01 MHC Tetramers Kit
easYmer HLA-B*15:01 MHC Tetramers Developed and Manufactured by immunAware
Materials Included:
The easYmer kit contains a peptide receptive preparation of HLA, a folding buffer, a positive control peptide for HLA-complex folding. The exact identities of these components are given below:
- easYmer: HLA-B*15:01 – peptide receptive, biotinylated in Tris/Maleate pH 7 with 30% Glycerol
- Folding Buffer: Tris/Maleate pH7
- Peptide: FAKPAGTPM, a stable HLA-B*15:01 binder. Positive control for evaluation analysis of peptide-HLA folding.
for Research Use Only
Available Sizes:
- 20 Tests (Sample-size)
- 50 Tests (Standard Size)
- 150 Tests
- 500 Tests
Key Benefits of easYmer® MHC Tetramers
- Ready-to-use
- One step loading
- Completely flexible and customizable*
- Biotinylated
- No special equipment needed
- Long shelf-life
*For Custom Tetramer Production, please Contact Us for more information
Assay Principle
This easYmer HLA-B*15:01 MHC Tetramers protocol is designed to evaluate the efficiency of peptide-HLA-I interaction and complex formation. The assay is based on detecting the ß2-microglobulin (ß2m? light chain subunit of recombinant HLA Class I (HLA-I) comlexes, where the heavy chain has been biotin tagged. These tagged complexes are subsequently captured by streptavidin coated beads, labeled with PE-conjugated anti-human ß2m, and analyzed by flow cytometry. Since peptide-HLA-I complex formation is entirely peptide dependent, bead-associated signals will only be detected if the peptide in question supports the folding of the HLA-I allotype of interest; peptides that efficiently support folding will give strong signals whereas peptides that support folding sub-optimally, or not at all, will give moderate to non-detectable signals.
Products Related to easYmer HLA-B*15:01 MHC Tetramers
HLA-B*15:01 (SVKEDLVAY) Class I Tetramer
easYmer HLA-B*15:02 MHC Tetramers Kit
easYmer HLA-B*15:09 MHC Tetramers Kit
ebiomall.com
>
>
>
>
>
>
>
>
>
>
>
目前大量制备单抗的方法主要有两大系统,一是动物体内生产法,这是国内外实验室所广泛采用;另一是体外培养法。
(1)动物体内生产单抗的方法
迄今为止,通常情况下均采用动物体内生产单抗的方法,鉴于绝大多数动物用杂交瘤均由BALB/c小鼠的骨髓瘤细胞与同品系的脾细胞融合而得,因此使用的动物当然首选BALB/c小鼠。本方法即将杂交瘤细胞接种于小鼠腹腔内,在小鼠腹腔内生长杂交瘤,并产生腹水,因而可得到大量的腹水单抗且抗体浓度很高。可见该法操作简便、经济,不过,腹水中常混有小鼠的各种杂蛋白(包括Ig),因此在很多情况下要提纯后才能使用,而且还有污染动物病毒的危险,故而最好用SPF级小鼠。
(2)体外培养生产单抗的方法
总体上讲,杂交瘤细胞系并不是严格的贴壁依赖细胞(anchoragedependentcell,ADC),因此既可以进行单层细胞培养,又可以进行悬浮培养。杂交瘤细胞的单层细胞培养法是各个实验室最常用的手段,即将杂交瘤细胞加入培养瓶中,以含10-15%小牛血清的培养基培养,细胞浓度以1×106-2×106/ml为佳,然后收集培养上清,其中单抗含量约10-50ug/ml。显然,这种方法制备的单抗量极为有限,无疑是不适用于单抗的大规模生产。要想在体外大量制备单抗,就必须进行杂交瘤细胞的大量(高密度)培养。单位体积内细胞数量越多,细胞存活时间越长,单抗的浓度就越高,产量就越大。
二、补体(complement,C)是存在于正常人和动物血清与组织液中的一组经活化后具有酶活性的蛋白质。早在19世纪末Bordet即证实,新鲜血液中含有一种不耐热的成分,可辅助和补充特异性抗体,介导免疫溶菌、溶血作用,故称为补体。补体是由30余种可溶性蛋白、膜结合性蛋白和补体受体组成的多分子系统,故称为补体系统(complementsystem)。根据补体系统各成分的生物学功能,可将其分为补体固有成分、补体调控成分和补体受体(CR)。

